LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis

By LabMedica International staff writers
Posted on 17 May 2024
Print article
Image: Images of invasive ductal carcinoma, mucinous carcinoma, and papillary carcinoma (Photo courtesy of Science China Press)
Image: Images of invasive ductal carcinoma, mucinous carcinoma, and papillary carcinoma (Photo courtesy of Science China Press)

Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E histology, are demanding in terms of time, resources, and labor and also raise concerns about specimen consumption. D-FFOCT, a high-resolution optical imaging technology, allows for the quick generation of virtual histology. Researchers have now developed an intraoperative diagnostic workflow that uses deep learning algorithms to classify tumors from D-FFOCT images, offering rapid and automated diagnosis for surgical decision-making.

A prospective cohort study conducted by researchers from Peking University People’s Hospital (Beijing, China) included 224 breast samples imaged using D-FFOCT. This imaging technique is non-destructive and requires no tissue preparation or staining. The D-FFOCT images were segmented into patches, and slides were allocated into a training set (182 slides, 10,357 patches) and an external testing set (42 slides, 3,140 patches) based on the order in which they were collected. A five-fold cross-validation method was employed to train and fine-tune the model. A machine learning model aggregated the patch prediction results to the slide level after feature extraction.

The testing set showed the model performed well at the patch level, identifying breast tissue types with an AUC of 0.926 (95% CI: 0.907–0.943). At the slide level, the diagnostic accuracy reached 97.62%, with a sensitivity of 96.88% and a specificity of 100%. Accuracy did not significantly differ across various molecular subtypes and histologic tumor types of breast cancer. Visualization heatmaps demonstrated that the deep learning models could identify features corresponding to metabolically active cell clusters in D-FFOCT images, aligning with expert assessments. This image analysis approach could potentially extend to various tumor types, given the conserved features detected in the model. In a margin simulation experiment, the diagnosis process took about three minutes, with the deep learning model achieving a high accuracy of 95.24%.

Based on the results, the study has proposed an intraoperative cancer diagnosis workflow integrating D-FFOCT with a deep learning model. In simulated intraoperative margin diagnosis, the workflow substantially reduced diagnosis time by about tenfold compared to traditional methods and proved to be highly cost-effective in terms of labor. No tissue was destroyed during optical imaging and analysis. Overall, this workflow offers a transparent solution for rapid and accurate intraoperative diagnosis, potentially guiding surgical decisions effectively.

Related Links:
Peking University People’s Hospital 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.